The study will have 1420 subjects, with three cohorts examining different regimens of the current Pfizer-BioNTech COVID vaccine or an Omicron-based vaccine. The first participants enrolled in clinical trial received Omicron-based vaccine candidate as a two-dose primary series and as a booster dose.
